Quretech Bio

Executive Summary

Quretech Bio, a Swedish biotechnology company based in Umeå, is pioneering a novel class of antibacterial agents called GmPcides. Unlike traditional antibiotics that kill bacteria directly, GmPcides disarm pathogens by inhibiting crucial protein-protein interactions involved in virulence, thereby neutralizing their ability to cause infection while preserving the host microbiome. This innovative approach aims to combat antimicrobial resistance (AMR) by restoring susceptibility to existing antibiotics and reducing selective pressure for resistance development. Founded in 2018, the company leverages deep expertise in bacterial pathogenesis and structural biology to advance its pipeline, with a focus on Gram-negative pathogens that pose the greatest clinical threat. Despite being in early preclinical stages, Quretech Bio's platform holds transformative potential to address the global AMR crisis. The company's strategy of targeting virulence rather than viability offers a promising pathway to overcome resistance mechanisms that render conventional antibiotics ineffective. With strong scientific foundations and a clear unmet medical need, Quretech Bio is positioned to attract strategic partnerships and funding to advance its lead candidate toward clinical development. The next 12-18 months will be critical for demonstrating preclinical proof-of-concept and establishing clinical feasibility.

Upcoming Catalysts (preview)

• Q3 2026Selection of clinical candidate for GmPcide program70% success
• Q4 2026Initiation of IND-enabling studies60% success
• H2 2026Partnership with major pharma for AMR program30% success